drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB11581 | DB11979 | 1,456 | 1,320 | [
"DDInter1926",
"DDInter625"
] | Venetoclax | Elagolix | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1456,
24,
1320
]
],
[
[
1456,
64,
271
],
[
271,
23,
1320
]
],
[
[
1456,
24,
1612
],
[
1612,
23,
1320
]
],
[
[
1456,
64,
79
],
[
79,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",... | Venetoclax may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Elagolix
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a ... |
DB00844 | DB06282 | 314 | 516 | [
"DDInter1257",
"DDInter1053"
] | Nalbuphine | Levocetirizine | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
314,
24,
516
]
],
[
[
314,
63,
701
],
[
701,
24,
516
]
],
[
[
314,
25,
407
],
[
407,
63,
516
]
],
[
[
314,
40,
421
],
[
421,
24,... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Nalbuphine may lead to a major life threatening interaction when taken with Opium and Opium may cause a mode... |
DB08889 | DB11003 | 350 | 748 | [
"DDInter299",
"DDInter100"
] | Carfilzomib | Anthrax vaccine | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
350,
24,
748
]
],
[
[
350,
63,
168
],
[
168,
24,
748
]
],
[
[
350,
25,
676
],
[
676,
63,
748
]
],
[
[
350,
64,
1057
],
[
1057,
2... | [
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
... | Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Carfilzomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib... |
DB00431 | DB01618 | 1,503 | 776 | [
"DDInter1072",
"DDInter1239"
] | Lindane | Molindone | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
1503,
24,
776
]
],
[
[
1503,
21,
28787
],
[
28787,
60,
776
]
],
[
[
1503,
24,
1662
],
[
1662,
63,
776
]
],
[
[
1503,
24,
1264
],
[
126... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by... | Lindane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Molindone (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00420 | DB01344 | 508 | 1,231 | [
"DDInter1532",
"DDInter1830"
] | Promazine | Tolevamer | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Moderate | 1 | [
[
[
508,
24,
1231
]
],
[
[
508,
62,
417
],
[
417,
24,
1231
]
],
[
[
508,
40,
1178
],
[
1178,
24,
1231
]
],
[
[
508,
24,
870
],
[
870,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevamer"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"... | Promazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer
Promazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that ... |
DB04843 | DB11130 | 1,511 | 407 | [
"DDInter1149",
"DDInter1344"
] | Mepenzolate | Opium | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1511,
24,
407
]
],
[
[
1511,
63,
662
],
[
662,
24,
407
]
],
[
[
1511,
24,
1241
],
[
1241,
24,
407
]
],
[
[
1511,
62,
685
],
[
685,
... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
... | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and ... |
DB01176 | DB01233 | 537 | 1,311 | [
"DDInter453",
"DDInter1197"
] | Cyclizine | Metoclopramide | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
537,
24,
1311
]
],
[
[
537,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
537,
63,
1020
],
[
1020,
24,
1311
]
],
[
[
537,
24,
643
],
[
643,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cyclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is ... | Cyclizine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Metoc... |
DB01142 | DB04575 | 1,264 | 35 | [
"DDInter593",
"DDInter1555"
] | Doxepin | Quinestrol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | The 3-cyclopentyl ether of ethinyl estradiol. | Minor | 0 | [
[
[
1264,
23,
35
]
],
[
[
1264,
23,
890
],
[
890,
1,
35
]
],
[
[
1264,
62,
559
],
[
559,
1,
35
]
],
[
[
1264,
63,
752
],
[
752,
23,
... | [
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinestrol"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mestranol"
],
[
"Mestra... | Doxepin may cause a minor interaction that can limit clinical effects when taken with Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Doxepin may cause a minor interaction that can limit clinical effects when taken with Estrone and Estrone (Compound) resembles Quinestrol (Compound)
Doxepin may cause ... |
DB00015 | DB00686 | 582 | 383 | [
"DDInter1585",
"DDInter1424"
] | Reteplase | Pentosan polysulfate | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Moderate | 1 | [
[
[
582,
24,
383
]
],
[
[
582,
24,
714
],
[
714,
63,
383
]
],
[
[
582,
25,
405
],
[
405,
63,
383
]
],
[
[
582,
24,
1061
],
[
1061,
2... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
... | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate
Reteplase may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib ... |
DB01088 | DB01324 | 714 | 178 | [
"DDInter908",
"DDInter1490"
] | Iloprost | Polythiazide | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
714,
24,
178
]
],
[
[
714,
63,
674
],
[
674,
40,
178
]
],
[
[
714,
63,
126
],
[
126,
23,
178
]
],
[
[
714,
63,
848
],
[
848,
24,... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction tha... |
DB00477 | DB01211 | 216 | 609 | [
"DDInter363",
"DDInter393"
] | Chlorpromazine | Clarithromycin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
216,
24,
609
]
],
[
[
216,
6,
4973
],
[
4973,
45,
609
]
],
[
[
216,
7,
8733
],
[
8733,
57,
609
]
],
[
[
216,
21,
28662
],
[
28662,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (C... | Chlorpromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Chlorpromazine (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Clarithromycin (Compound)
Chlorpromazine (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Clarithromycin... |
DB00991 | DB13074 | 97 | 877 | [
"DDInter1358",
"DDInter1110"
] | Oxaprozin | Macimorelin | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
97,
24,
877
]
],
[
[
97,
63,
1479
],
[
1479,
24,
877
]
],
[
[
97,
24,
1662
],
[
1662,
24,
877
]
],
[
[
97,
1,
1236
],
[
1236,
24... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Pi... |
DB01068 | DB01142 | 1,565 | 1,264 | [
"DDInter411",
"DDInter593"
] | Clonazepam | Doxepin | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1565,
24,
1264
]
],
[
[
1565,
24,
401
],
[
401,
24,
1264
]
],
[
[
1565,
63,
832
],
[
832,
24,
1264
]
],
[
[
1565,
24,
649
],
[
649,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and T... |
DB00106 | DB01236 | 618 | 679 | [
"DDInter4",
"DDInter1664"
] | Abarelix | Sevoflurane | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
618,
24,
679
]
],
[
[
618,
24,
1262
],
[
1262,
40,
679
]
],
[
[
618,
23,
112
],
[
112,
23,
679
]
],
[
[
618,
24,
484
],
[
484,
6... | [
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can lim... |
DB01110 | DB01591 | 86 | 667 | [
"DDInter1209",
"DDInter1696"
] | Miconazole | Solifenacin | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
86,
24,
667
]
],
[
[
86,
6,
8374
],
[
8374,
45,
667
]
],
[
[
86,
21,
29429
],
[
29429,
60,
667
]
],
[
[
86,
24,
392
],
[
392,
24... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Miconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Miconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Miconazole (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Solifenacin (Compound)
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lapat... |
DB00798 | DB01050 | 1,132 | 848 | [
"DDInter815",
"DDInter900"
] | Gentamicin | Ibuprofen | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1132,
24,
848
]
],
[
[
1132,
6,
10612
],
[
10612,
45,
848
]
],
[
[
1132,
21,
28929
],
[
28929,
60,
848
]
],
[
[
1132,
63,
831
],
[
831... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Gentamicin",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)"... | Gentamicin (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Ibuprofen (Compound)
Gentamicin (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Ibuprofen (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Ind... |
DB00489 | DB12267 | 17 | 1,476 | [
"DDInter1704",
"DDInter233"
] | Sotalol | Brigatinib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
17,
24,
1476
]
],
[
[
17,
25,
918
],
[
918,
24,
1476
]
],
[
[
17,
63,
176
],
[
176,
24,
1476
]
],
[
[
17,
64,
79
],
[
79,
24,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",... | Sotalol may lead to a major life threatening interaction when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine ... |
DB01097 | DB01101 | 1,377 | 60 | [
"DDInter1033",
"DDInter285"
] | Leflunomide | Capecitabine | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Major | 2 | [
[
[
1377,
25,
60
]
],
[
[
1377,
6,
6017
],
[
6017,
45,
60
]
],
[
[
1377,
21,
28906
],
[
28906,
60,
60
]
],
[
[
1377,
64,
1176
],
[
1176,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capecitabine"
]
],
[
[
"Leflunomide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Cap... | Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Capecitabine (Compound)
Leflunomide (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Capecitabine (Compound)
Leflunomide may lead to a major life threatening interaction when taken with Moxifloxacin an... |
DB00741 | DB12500 | 167 | 283 | [
"DDInter885",
"DDInter714"
] | Hydrocortisone | Fedratinib | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
167,
24,
283
]
],
[
[
167,
24,
351
],
[
351,
23,
283
]
],
[
[
167,
63,
122
],
[
122,
23,
283
]
],
[
[
167,
63,
1419
],
[
1419,
2... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and V... |
DB00328 | DB00927 | 831 | 1,559 | [
"DDInter921",
"DDInter712"
] | Indomethacin | Famotidine | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Minor | 0 | [
[
[
831,
23,
1559
]
],
[
[
831,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
831,
21,
28826
],
[
28826,
60,
1559
]
],
[
[
831,
40,
24
],
[
24,
... | [
[
[
"Indomethacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Famotidine"
]
],
[
[
"Indomethacin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compoun... | Indomethacin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Indomethacin (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Famotidine (Compound)
Indomethacin (Compound) resembles Tolmetin (Compound) and Tolmetin may cause a minor interaction that can ... |
DB00476 | DB00619 | 109 | 1,419 | [
"DDInter608",
"DDInter909"
] | Duloxetine | Imatinib | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
109,
24,
1419
]
],
[
[
109,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
109,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
109,
25,
222
],
[
222,... | [
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Duloxetine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Duloxetine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Duloxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may ... |
DB00290 | DB09074 | 329 | 1,362 | [
"DDInter219",
"DDInter1327"
] | Bleomycin | Olaparib | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
329,
24,
1362
]
],
[
[
329,
24,
896
],
[
896,
24,
1362
]
],
[
[
329,
63,
552
],
[
552,
24,
1362
]
],
[
[
329,
24,
385
],
[
385,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine m... |
DB00691 | DB09268 | 1,058 | 1,662 | [
"DDInter1237",
"DDInter1464"
] | Moexipril | Picosulfuric acid | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1058,
24,
1662
]
],
[
[
1058,
24,
708
],
[
708,
24,
1662
]
],
[
[
1058,
63,
1573
],
[
1573,
24,
1662
]
],
[
[
1058,
40,
1638
],
[
1638... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Prednisone... |
DB09083 | DB12500 | 880 | 283 | [
"DDInter996",
"DDInter714"
] | Ivabradine | Fedratinib | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
880,
25,
283
]
],
[
[
880,
25,
351
],
[
351,
23,
283
]
],
[
[
880,
64,
1593
],
[
1593,
23,
283
]
],
[
[
880,
64,
1419
],
[
1419,
... | [
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} m... | Ivabradine may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Ivabradine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interacti... |
DB09312 | DB11817 | 967 | 1,259 | [
"DDInter103",
"DDInter165"
] | Antilymphocyte immunoglobulin (horse) | Baricitinib | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
967,
25,
1259
]
],
[
[
967,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
967,
24,
949
],
[
949,
24,
1259
]
],
[
[
967,
24,
1129
],
[
1129,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v... | Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that coul... |
DB00327 | DB06691 | 421 | 849 | [
"DDInter890",
"DDInter1155"
] | Hydromorphone | Mepyramine | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 a... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
421,
24,
849
]
],
[
[
421,
24,
1594
],
[
1594,
24,
849
]
],
[
[
421,
6,
12523
],
[
12523,
45,
849
]
],
[
[
421,
1,
828
],
[
828,
... | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Hydromorphone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Hydromorphon... |
DB01177 | DB06699 | 77 | 774 | [
"DDInter904",
"DDInter493"
] | Idarubicin | Degarelix | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
77,
24,
774
]
],
[
[
77,
63,
521
],
[
521,
1,
774
]
],
[
[
77,
21,
29232
],
[
29232,
60,
774
]
],
[
[
77,
62,
112
],
[
112,
23,
... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Idarubicin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Idarubicin may cause a minor interaction that ca... |
DB00372 | DB01174 | 999 | 697 | [
"DDInter1793",
"DDInter1442"
] | Thiethylperazine | Phenobarbital | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
999,
24,
697
]
],
[
[
999,
24,
759
],
[
759,
1,
697
]
],
[
[
999,
63,
362
],
[
362,
1,
697
]
],
[
[
999,
24,
536
],
[
536,
40,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbit... |
DB00970 | DB01059 | 0 | 956 | [
"DDInter466",
"DDInter1313"
] | Dactinomycin | Norfloxacin | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
0,
23,
956
]
],
[
[
0,
23,
872
],
[
872,
40,
956
]
],
[
[
0,
62,
1176
],
[
1176,
1,
956
]
],
[
[
0,
23,
1539
],
[
1539,
1,
... | [
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Dactinomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
[... | Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (... |
DB00496 | DB00719 | 194 | 1,219 | [
"DDInter480",
"DDInter149"
] | Darifenacin | Azatadine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Moderate | 1 | [
[
[
194,
24,
1219
]
],
[
[
194,
63,
13
],
[
13,
24,
1219
]
],
[
[
194,
24,
830
],
[
830,
1,
1219
]
],
[
[
194,
6,
8374
],
[
8374,
45... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine... |
DB00626 | DB09134 | 1,441 | 1,552 | [
"DDInter161",
"DDInter966"
] | Bacitracin | Ioversol | Bacitracin is a combination of at least 9 bacitracins.[A955,A181952] 60-80% of commercially prepared bacitracin is bacitracin A. The bacillus that produces bacitracin was first isolated from a knee scrape in 1945 from the knee wound of a child named Margaret Tracy. Bacitracin was granted FDA approval on 29 July 1948.[A... | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Major | 2 | [
[
[
1441,
25,
1552
]
],
[
[
1441,
24,
242
],
[
242,
63,
1552
]
],
[
[
1441,
25,
1448
],
[
1448,
25,
1552
]
],
[
[
1441,
63,
963
],
[
963,
... | [
[
[
"Bacitracin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioversol"
]
],
[
[
"Bacitracin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",... | Bacitracin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Ioversol
Bacitracin may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may lead... |
DB09076 | DB13913 | 1,116 | 1,536 | [
"DDInter1899",
"DDInter175"
] | Umeclidinium | Belladonna | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_. Its roots, leaves and fruits contain , , and mostly, . These alkaloids are naturally-occurring muscarinic antagonists. is a non-selective muscarinic antagonist that is mainly used as ... | Moderate | 1 | [
[
[
1116,
24,
1536
]
],
[
[
1116,
63,
849
],
[
849,
24,
1536
]
],
[
[
1116,
24,
412
],
[
412,
24,
1536
]
],
[
[
1116,
63,
849
],
[
849,
... | [
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belladonna"
]
],
[
[
"Umeclidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
... | Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Belladonna
Umeclidinium may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and E... |
DB00574 | DB08875 | 121 | 1,618 | [
"DDInter717",
"DDInter262"
] | Fenfluramine | Cabozantinib | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
121,
24,
1618
]
],
[
[
121,
24,
1032
],
[
1032,
63,
1618
]
],
[
[
121,
24,
480
],
[
480,
24,
1618
]
],
[
[
121,
25,
41
],
[
41,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Formote... |
DB00559 | DB08895 | 152 | 976 | [
"DDInter223",
"DDInter1825"
] | Bosentan | Tofacitinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
152,
24,
976
]
],
[
[
152,
24,
214
],
[
214,
63,
976
]
],
[
[
152,
25,
1017
],
[
1017,
63,
976
]
],
[
[
152,
24,
86
],
[
86,
24,... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Bosentan may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause... |
DB01276 | DB09100 | 123 | 320 | [
"DDInter706",
"DDInter1799"
] | Exenatide | Thyroid, porcine | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
123,
24,
320
]
],
[
[
123,
63,
417
],
[
417,
23,
320
]
],
[
[
123,
63,
1144
],
[
1144,
24,
320
]
],
[
[
123,
24,
1296
],
[
1296,
... | [
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
... | Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nat... |
DB00341 | DB01589 | 1,242 | 481 | [
"DDInter343",
"DDInter1552"
] | Cetirizine | Quazepam | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
1242,
24,
481
]
],
[
[
1242,
24,
1216
],
[
1216,
1,
481
]
],
[
[
1242,
63,
905
],
[
905,
40,
481
]
],
[
[
1242,
63,
1174
],
[
1174,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
Cetiri... |
DB00682 | DB05541 | 126 | 801 | [
"DDInter1951",
"DDInter239"
] | Warfarin | Brivaracetam | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam . It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 . | Minor | 0 | [
[
[
126,
23,
801
]
],
[
[
126,
23,
477
],
[
477,
23,
801
]
],
[
[
126,
24,
101
],
[
101,
23,
801
]
],
[
[
126,
63,
1215
],
[
1215,
2... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brivaracetam"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
],
[
"C... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlans... |
DB00388 | DB01170 | 1,636 | 1,150 | [
"DDInter1453",
"DDInter846"
] | Phenylephrine | Guanethidine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem] | Moderate | 1 | [
[
[
1636,
24,
1150
]
],
[
[
1636,
63,
73
],
[
73,
24,
1150
]
],
[
[
1636,
24,
1344
],
[
1344,
63,
1150
]
],
[
[
1636,
1,
874
],
[
874,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanethidine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Guanethidine
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Canaglifloz... |
DB01144 | DB09564 | 1,326 | 1,296 | [
"DDInter540",
"DDInter930"
] | Diclofenamide | Insulin degludec | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1326,
24,
1296
]
],
[
[
1326,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
1326,
24,
659
],
[
659,
24,
1296
]
],
[
[
1326,
64,
1645
],
[
1645... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Vilante... |
DB00872 | DB14568 | 1,080 | 982 | [
"DDInter438",
"DDInter1000"
] | Conivaptan | Ivosidenib | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
1080,
25,
982
]
],
[
[
1080,
63,
168
],
[
168,
23,
982
]
],
[
[
1080,
62,
1101
],
[
1101,
23,
982
]
],
[
[
1080,
64,
608
],
[
608,
... | [
[
[
"Conivaptan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib... | Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene... |
DB00305 | DB10795 | 377 | 221 | [
"DDInter1232",
"DDInter1486"
] | Mitomycin | Poliovirus type 1 antigen (formaldehyde inactivated) | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
377,
24,
221
]
],
[
[
377,
64,
581
],
[
581,
24,
221
]
],
[
[
377,
63,
599
],
[
599,
24,
221
]
],
[
[
377,
24,
322
],
[
322,
24,... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"In... | Mitomycin may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00863 | DB11613 | 1,194 | 1,519 | [
"DDInter1568",
"DDInter1924"
] | Ranitidine | Velpatasvir | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
1194,
24,
1519
]
],
[
[
1194,
24,
594
],
[
594,
24,
1519
]
],
[
[
1194,
23,
1384
],
[
1384,
24,
1519
]
],
[
[
1194,
40,
1127
],
[
1127... | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
... | Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate and Magaldrat... |
DB09065 | DB09389 | 760 | 517 | [
"DDInter424",
"DDInter1315"
] | Cobicistat | Norgestrel | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
760,
24,
517
]
],
[
[
760,
63,
14
],
[
14,
23,
517
]
],
[
[
760,
25,
159
],
[
159,
63,
517
]
],
[
[
760,
63,
86
],
[
86,
24,
... | [
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Cobicistat may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib ma... |
DB12267 | DB14443 | 1,476 | 987 | [
"DDInter233",
"DDInter1931"
] | Brigatinib | Vibrio cholerae CVD 103-HgR strain live antigen | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1476,
24,
987
]
],
[
[
1476,
63,
1468
],
[
1468,
24,
987
]
],
[
[
1476,
64,
1220
],
[
1220,
24,
987
]
],
[
[
1476,
24,
1619
],
[
1619,... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Brigatinib may lead to a major life threatening interaction when taken with D... |
DB00317 | DB04868 | 883 | 478 | [
"DDInter810",
"DDInter1293"
] | Gefitinib | Nilotinib | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
883,
24,
478
]
],
[
[
883,
6,
6017
],
[
6017,
45,
478
]
],
[
[
883,
7,
2703
],
[
2703,
46,
478
]
],
[
[
883,
18,
2183
],
[
2183,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Gefitinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Gefitinib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Gefitinib (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Nilotinib (Compound)
Gefitinib (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Gefitinib (Compound)... |
DB00749 | DB06605 | 59 | 1,409 | [
"DDInter699",
"DDInter108"
] | Etodolac | Apixaban | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
59,
25,
1409
]
],
[
[
59,
6,
6017
],
[
6017,
45,
1409
]
],
[
[
59,
21,
29666
],
[
29666,
60,
1409
]
],
[
[
59,
63,
1560
],
[
1560,
... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Etodolac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Apixaban"
... | Etodolac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Apixaban (Compound)
Etodolac (Compound) causes Melaena (Side Effect) and Melaena (Side Effect) is caused by Apixaban (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may... |
DB00081 | DB10795 | 273 | 221 | [
"DDInter1838",
"DDInter1486"
] | Tositumomab | Poliovirus type 1 antigen (formaldehyde inactivated) | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
273,
24,
221
]
],
[
[
273,
64,
581
],
[
581,
24,
221
]
],
[
[
273,
24,
599
],
[
599,
24,
221
]
],
[
[
273,
25,
1510
],
[
1510,
2... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Tositumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Tositumomab may cause a moderate interaction that could exacerbate diseases when tak... |
DB01232 | DB08895 | 1,327 | 976 | [
"DDInter1640",
"DDInter1825"
] | Saquinavir | Tofacitinib | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
1327,
25,
976
]
],
[
[
1327,
63,
660
],
[
660,
24,
976
]
],
[
[
1327,
25,
214
],
[
214,
63,
976
]
],
[
[
1327,
25,
868
],
[
868,
... | [
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomepr... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Saquinavir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib m... |
DB00575 | DB01041 | 1,020 | 770 | [
"DDInter412",
"DDInter1789"
] | Clonidine | Thalidomide | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1020,
24,
770
]
],
[
[
1020,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1020,
18,
2357
],
[
2357,
57,
770
]
],
[
[
1020,
21,
28789
],
[
28789... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Clonidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Clonidine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Clonidine (Compound) downregulates GRB7 (Gene) and GRB7 (Gene) is downregulated by Thalidomide (Compound)
Clonidine (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Tha... |
DB00656 | DB01169 | 827 | 57 | [
"DDInter1851",
"DDInter120"
] | Trazodone | Arsenic trioxide | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
827,
25,
57
]
],
[
[
827,
6,
8374
],
[
8374,
45,
57
]
],
[
[
827,
23,
112
],
[
112,
23,
57
]
],
[
[
827,
24,
603
],
[
603,
63,
... | [
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Trazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ars... | Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxide
Trazod... |
DB00722 | DB11921 | 743 | 1,019 | [
"DDInter1079",
"DDInter492"
] | Lisinopril | Deflazacort | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
743,
24,
1019
]
],
[
[
743,
24,
959
],
[
959,
24,
1019
]
],
[
[
743,
23,
286
],
[
286,
24,
1019
]
],
[
[
743,
63,
1512
],
[
1512,
... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and ... |
DB00495 | DB00877 | 139 | 629 | [
"DDInter1961",
"DDInter1678"
] | Zidovudine | Sirolimus | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
139,
24,
629
]
],
[
[
139,
6,
4973
],
[
4973,
45,
629
]
],
[
[
139,
6,
8155
],
[
8155,
46,
629
]
],
[
[
139,
7,
9681
],
[
9681,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Zidovudine (Compound) binds ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Sirolimus (Compound)
Zidovudine (Compound) upregulates THAP11 (Gene) and THAP11 (Gene) is downregulated by Sirolimus (Compound)
Zidovudine (Compound) cau... |
DB00975 | DB08886 | 1,317 | 637 | [
"DDInter573",
"DDInter126"
] | Dipyridamole | Asparaginase Erwinia chrysanthemi | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
1317,
24,
637
]
],
[
[
1317,
25,
936
],
[
936,
24,
637
]
],
[
[
1317,
63,
1274
],
[
1274,
24,
637
]
],
[
[
1317,
25,
1421
],
[
1421,
... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cangrelor"
... | Dipyridamole may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofe... |
DB00771 | DB01114 | 262 | 272 | [
"DDInter397",
"DDInter362"
] | Clidinium | Chlorpheniramine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
262,
24,
272
]
],
[
[
262,
24,
358
],
[
358,
63,
272
]
],
[
[
262,
63,
128
],
[
128,
24,
272
]
],
[
[
262,
24,
314
],
[
314,
24,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphenir... |
DB00717 | DB12332 | 1,197 | 1,619 | [
"DDInter1312",
"DDInter1626"
] | Norethisterone | Rucaparib | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1197,
24,
1619
]
],
[
[
1197,
24,
259
],
[
259,
24,
1619
]
],
[
[
1197,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
1197,
24,
1501
],
[
1501... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and I... |
DB11581 | DB14443 | 1,456 | 987 | [
"DDInter1926",
"DDInter1931"
] | Venetoclax | Vibrio cholerae CVD 103-HgR strain live antigen | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1456,
24,
987
]
],
[
[
1456,
64,
1468
],
[
1468,
24,
987
]
],
[
[
1456,
25,
351
],
[
351,
24,
987
]
],
[
[
1456,
24,
1583
],
[
1583,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponat... | Venetoclax may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Venetoclax may lead to a major life threatening interaction when taken with Ribociclib and R... |
DB00460 | DB12364 | 612 | 1,421 | [
"DDInter1929",
"DDInter200"
] | Verteporfin | Betrixaban | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
612,
24,
1421
]
],
[
[
612,
24,
714
],
[
714,
25,
1421
]
],
[
[
612,
63,
291
],
[
291,
25,
1421
]
],
[
[
612,
24,
714
],
[
714,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may lead to ... |
DB00283 | DB01452 | 701 | 993 | [
"DDInter395",
"DDInter532"
] | Clemastine | Diamorphine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
701,
24,
993
]
],
[
[
701,
24,
421
],
[
421,
40,
993
]
],
[
[
701,
24,
475
],
[
475,
25,
993
]
],
[
[
701,
24,
13
],
[
13,
24,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening int... |
DB01229 | DB11952 | 973 | 800 | [
"DDInter1378",
"DDInter612"
] | Paclitaxel (protein-bound) | Duvelisib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
973,
24,
800
]
],
[
[
973,
24,
310
],
[
310,
24,
800
]
],
[
[
973,
63,
467
],
[
467,
24,
800
]
],
[
[
973,
24,
1476
],
[
1476,
6... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Paclitaxel... |
DB00450 | DB00687 | 78 | 870 | [
"DDInter603",
"DDInter747"
] | Droperidol | Fludrocortisone | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Major | 2 | [
[
[
78,
25,
870
]
],
[
[
78,
25,
167
],
[
167,
40,
870
]
],
[
[
78,
21,
28835
],
[
28835,
60,
870
]
],
[
[
78,
24,
688
],
[
688,
62,... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",... | Droperidol may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Fludrocortisone (Compound)
Droperidol (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound)
Droperidol may cause a moderate... |
DB01041 | DB11632 | 770 | 580 | [
"DDInter1789",
"DDInter1343"
] | Thalidomide | Opicapone | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) in... | Moderate | 1 | [
[
[
770,
24,
580
]
],
[
[
770,
63,
104
],
[
104,
24,
580
]
],
[
[
770,
24,
830
],
[
830,
24,
580
]
],
[
[
770,
25,
1053
],
[
1053,
2... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and... |
DB00518 | DB12500 | 510 | 283 | [
"DDInter35",
"DDInter714"
] | Albendazole | Fedratinib | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
510,
24,
283
]
],
[
[
510,
24,
351
],
[
351,
23,
283
]
],
[
[
510,
24,
327
],
[
327,
24,
283
]
],
[
[
510,
63,
529
],
[
529,
24,... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Abametapir and Abamet... |
DB00555 | DB01142 | 706 | 1,264 | [
"DDInter1020",
"DDInter593"
] | Lamotrigine | Doxepin | Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
706,
24,
1264
]
],
[
[
706,
24,
401
],
[
401,
24,
1264
]
],
[
[
706,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
706,
24,
649
],
[
649,
... | [
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Lamotrigine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Lamotrigine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Dox... |
DB00794 | DB05679 | 759 | 1,683 | [
"DDInter1521",
"DDInter1907"
] | Primidone | Ustekinumab | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
759,
24,
1683
]
],
[
[
759,
24,
1042
],
[
1042,
24,
1683
]
],
[
[
759,
25,
1362
],
[
1362,
63,
1683
]
],
[
[
759,
24,
1093
],
[
1093,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
],
[... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Primidone may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cau... |
DB00396 | DB09098 | 989 | 98 | [
"DDInter1530",
"DDInter1700"
] | Progesterone (topical) | Somatrem | Progesterone can cause cancer according to an independent committee of scientific and health experts. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
989,
24,
98
]
],
[
[
989,
1,
284
],
[
284,
24,
98
]
],
[
[
989,
24,
159
],
[
159,
63,
98
]
],
[
[
989,
24,
609
],
[
609,
24,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Progesterone",
"{u} (Compound) resembles {v} (Compound)",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a mod... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone (Compound) resembles Finasteride (Compound) and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Progesterone may cause a moderate interaction that could... |
DB00938 | DB06706 | 455 | 468 | [
"DDInter1635",
"DDInter985"
] | Salmeterol | Isometheptene | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
455,
24,
468
]
],
[
[
455,
18,
3023
],
[
3023,
57,
468
]
],
[
[
455,
24,
480
],
[
480,
24,
468
]
],
[
[
455,
63,
1100
],
[
1100,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Salmeterol",
"{u} (Compound) downregulates {v} (Gene)",
"RUVBL1"
],
[
"RUVBL1",
"{u} (Gene) is downregulated ... | Salmeterol (Compound) downregulates RUVBL1 (Gene) and RUVBL1 (Gene) is downregulated by Isometheptene (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isomethept... |
DB08899 | DB09098 | 129 | 98 | [
"DDInter649",
"DDInter1700"
] | Enzalutamide | Somatrem | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
129,
24,
98
]
],
[
[
129,
25,
1612
],
[
1612,
62,
98
]
],
[
[
129,
62,
608
],
[
608,
23,
98
]
],
[
[
129,
64,
168
],
[
168,
23,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Fostems... | Enzalutamide may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a ... |
DB01396 | DB09472 | 1,482 | 1,383 | [
"DDInter553",
"DDInter1693"
] | Digitoxin | Sodium sulfate | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Minor | 0 | [
[
[
1482,
23,
1383
]
],
[
[
1482,
40,
1252
],
[
1252,
23,
1383
]
],
[
[
1482,
63,
609
],
[
609,
24,
1383
]
],
[
[
1482,
24,
1154
],
[
1154... | [
[
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interac... | Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate
Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that cou... |
DB00477 | DB01087 | 216 | 1,520 | [
"DDInter363",
"DDInter1520"
] | Chlorpromazine | Primaquine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
216,
24,
1520
]
],
[
[
216,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
216,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
216,
21,
28852
],
[
2885... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
... | Chlorpromazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Chlorpromazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Chlorpromazine (Compound... |
DB04868 | DB06772 | 478 | 310 | [
"DDInter1293",
"DDInter259"
] | Nilotinib | Cabazitaxel | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
478,
24,
310
]
],
[
[
478,
63,
973
],
[
973,
24,
310
]
],
[
[
478,
6,
4973
],
[
4973,
45,
310
]
],
[
[
478,
21,
28894
],
[
28894,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Nilotinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Cabazitaxel (Compound)
Nilotinib (Compound)... |
DB08816 | DB08893 | 578 | 271 | [
"DDInter1802",
"DDInter1229"
] | Ticagrelor | Mirabegron | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Minor | 0 | [
[
[
578,
23,
271
]
],
[
[
578,
62,
1523
],
[
1523,
40,
271
]
],
[
[
578,
6,
4973
],
[
4973,
45,
271
]
],
[
[
578,
21,
28722
],
[
28722,
... | [
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
]
],
[
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Labetalol"
],
[
"... | Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Labetalol and Labetalol (Compound) resembles Mirabegron (Compound)
Ticagrelor (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Mirabegron (Compound)
Ticagrelor (Compound) causes Nausea (Side Effect) and Nausea (Side Effec... |
DB00701 | DB08882 | 1,091 | 1,281 | [
"DDInter90",
"DDInter1070"
] | Amprenavir | Linagliptin | Amprenavir is a protease inhibitor used to treat HIV infection. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1091,
24,
1281
]
],
[
[
1091,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1091,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1091,
21,
29081
],
[
290... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Amprenavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Amprenavir (Compound) causes Angioedema (Side Effect) and Angioe... |
DB00808 | DB01124 | 1,605 | 1,411 | [
"DDInter916",
"DDInter1828"
] | Indapamide | Tolbutamide | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1605,
24,
1411
]
],
[
[
1605,
24,
959
],
[
959,
40,
1411
]
],
[
[
1605,
63,
245
],
[
245,
40,
1411
]
],
[
[
1605,
21,
28746
],
[
28746... | [
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Indapamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00443 | DB15093 | 251 | 1,654 | [
"DDInter195",
"DDInter1698"
] | Betamethasone | Somapacitan | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
251,
24,
1654
]
],
[
[
251,
24,
433
],
[
433,
24,
1654
]
],
[
[
251,
63,
176
],
[
176,
24,
1654
]
],
[
[
251,
40,
167
],
[
167,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Insulin ... |
DB00782 | DB01173 | 1,123 | 358 | [
"DDInter1535",
"DDInter1349"
] | Propantheline | Orphenadrine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
1123,
24,
358
]
],
[
[
1123,
24,
211
],
[
211,
1,
358
]
],
[
[
1123,
24,
272
],
[
272,
24,
358
]
],
[
[
1123,
24,
820
],
[
820,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate ... |
DB06688 | DB09570 | 1,430 | 1,480 | [
"DDInter1677",
"DDInter1002"
] | Sipuleucel-T | Ixazomib | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
1430,
24,
1480
]
],
[
[
1430,
63,
268
],
[
268,
24,
1480
]
],
[
[
1430,
24,
310
],
[
310,
24,
1480
]
],
[
[
1430,
24,
110
],
[
110,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB08893 | DB12130 | 271 | 1,017 | [
"DDInter1229",
"DDInter1094"
] | Mirabegron | Lorlatinib | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Minor | 0 | [
[
[
271,
23,
1017
]
],
[
[
271,
62,
1101
],
[
1101,
23,
1017
]
],
[
[
271,
62,
126
],
[
126,
24,
1017
]
],
[
[
271,
64,
888
],
[
888,
... | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Mirabegron may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may c... |
DB00518 | DB04855 | 510 | 540 | [
"DDInter35",
"DDInter602"
] | Albendazole | Dronedarone | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Moderate | 1 | [
[
[
510,
24,
540
]
],
[
[
510,
6,
8374
],
[
8374,
45,
540
]
],
[
[
510,
21,
28883
],
[
28883,
60,
540
]
],
[
[
510,
62,
608
],
[
608,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Albendazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Albendazole (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Albendazole may cause a minor interaction that can limit clinical effects when taken with Lidocain... |
DB00264 | DB09333 | 88 | 278 | [
"DDInter1200",
"DDInter963"
] | Metoprolol | Iopodic acid | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Iopodic acid, also known by the name of ipodate, is classified as a cholecystographic agent formed by a weak organic acid that contains a tri-iodinated benzene ring with iodine at positions 2, 4 and 6. Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was devel... | Moderate | 1 | [
[
[
88,
24,
278
]
],
[
[
88,
63,
1648
],
[
1648,
24,
278
]
],
[
[
88,
24,
1527
],
[
1527,
24,
278
]
],
[
[
88,
40,
726
],
[
726,
24,... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid a... |
DB00549 | DB08903 | 522 | 996 | [
"DDInter1955",
"DDInter170"
] | Zafirlukast | Bedaquiline | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
522,
24,
996
]
],
[
[
522,
6,
8374
],
[
8374,
45,
996
]
],
[
[
522,
21,
29106
],
[
29106,
60,
996
]
],
[
[
522,
24,
112
],
[
112,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Zafirlukast (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Bedaquiline (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and ... |
DB06335 | DB11652 | 761 | 1,155 | [
"DDInter1646",
"DDInter1891"
] | Saxagliptin | Tucatinib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
761,
24,
1155
]
],
[
[
761,
63,
222
],
[
222,
23,
1155
]
],
[
[
761,
64,
1101
],
[
1101,
23,
1155
]
],
[
[
761,
24,
659
],
[
659,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Saxagliptin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause... |
DB01118 | DB04845 | 33 | 309 | [
"DDInter76",
"DDInter1001"
] | Amiodarone | Ixabepilone | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
33,
24,
309
]
],
[
[
33,
6,
8374
],
[
8374,
45,
309
]
],
[
[
33,
21,
29269
],
[
29269,
60,
309
]
],
[
[
33,
63,
1419
],
[
1419,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Amiodarone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Amiodarone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Amiodarone (Compound) causes Menopausal symptoms (Side Effect) and Menopausal symptoms (Side Effect) is caused by Ixabepilone (Compound)
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB06228 | DB11828 | 792 | 1,406 | [
"DDInter1609",
"DDInter1281"
] | Rivaroxaban | Neratinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
792,
24,
1406
]
],
[
[
792,
63,
392
],
[
392,
24,
1406
]
],
[
[
792,
25,
1421
],
[
1421,
63,
1406
]
],
[
[
792,
24,
1456
],
[
1456,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Rivaroxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a... |
DB01240 | DB11689 | 885 | 321 | [
"DDInter657",
"DDInter1659"
] | Epoprostenol | Selumetinib | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
885,
24,
321
]
],
[
[
885,
63,
291
],
[
291,
24,
321
]
],
[
[
885,
25,
498
],
[
498,
24,
321
]
],
[
[
885,
25,
1421
],
[
1421,
6... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Argatroban"
],
... | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Epoprostenol may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause... |
DB09570 | DB10315 | 1,480 | 1,137 | [
"DDInter1002",
"DDInter1127"
] | Ixazomib | Measles virus vaccine live attenuated | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
1480,
25,
1137
]
],
[
[
1480,
64,
581
],
[
581,
25,
1137
]
],
[
[
1480,
63,
384
],
[
384,
25,
1137
]
],
[
[
1480,
25,
676
],
[
676,
... | [
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"In... | Ixazomib may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib ma... |
DB00470 | DB00594 | 530 | 863 | [
"DDInter601",
"DDInter68"
] | Dronabinol | Amiloride | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions... | Moderate | 1 | [
[
[
530,
24,
863
]
],
[
[
530,
21,
28645
],
[
28645,
60,
863
]
],
[
[
530,
63,
1648
],
[
1648,
24,
863
]
],
[
[
530,
25,
593
],
[
593,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiloride"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Cough"
],
[
"Cough",
"{u} (Side Effect) is caused by {v}... | Dronabinol (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Amiloride (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amiloride
Dron... |
DB00095 | DB15699 | 66 | 652 | [
"DDInter623",
"DDInter232"
] | Efalizumab | Brexucabtagene autoleucel | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Moderate | 1 | [
[
[
66,
24,
652
]
],
[
[
66,
24,
259
],
[
259,
24,
652
]
],
[
[
66,
63,
1184
],
[
1184,
24,
652
]
],
[
[
66,
25,
976
],
[
976,
25,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
... | Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Anakin... |
DB01050 | DB11703 | 848 | 405 | [
"DDInter900",
"DDInter9"
] | Ibuprofen | Acalabrutinib | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
848,
25,
405
]
],
[
[
848,
63,
139
],
[
139,
24,
405
]
],
[
[
848,
24,
643
],
[
643,
24,
405
]
],
[
[
848,
24,
1598
],
[
1598,
6... | [
[
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudin... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and D... |
DB00331 | DB01324 | 1,645 | 178 | [
"DDInter1164",
"DDInter1490"
] | Metformin | Polythiazide | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
1645,
24,
178
]
],
[
[
1645,
24,
674
],
[
674,
40,
178
]
],
[
[
1645,
21,
28714
],
[
28714,
60,
178
]
],
[
[
1645,
63,
352
],
[
352,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
],
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Metformin (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Polythiazide (Compound)
Metformin may cause a modera... |
DB00026 | DB06772 | 1,184 | 310 | [
"DDInter94",
"DDInter259"
] | Anakinra | Cabazitaxel | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
1184,
24,
310
]
],
[
[
1184,
24,
973
],
[
973,
24,
310
]
],
[
[
1184,
24,
800
],
[
800,
63,
310
]
],
[
[
1184,
23,
1461
],
[
1461,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib ... |
DB00357 | DB04868 | 1,051 | 478 | [
"DDInter71",
"DDInter1293"
] | Aminoglutethimide | Nilotinib | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1051,
24,
478
]
],
[
[
1051,
24,
1468
],
[
1468,
63,
478
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
478
]
],
[
[
1051,
21,
28762
],
[
28762... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
... | Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Aminoglu... |
DB09075 | DB15233 | 498 | 1,650 | [
"DDInter621",
"DDInter142"
] | Edoxaban | Avapritinib | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
498,
25,
1650
]
],
[
[
498,
64,
1478
],
[
1478,
24,
1650
]
],
[
[
498,
63,
557
],
[
557,
24,
1650
]
],
[
[
498,
25,
1320
],
[
1320,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may ca... | Edoxaban may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may... |
DB00687 | DB10343 | 870 | 962 | [
"DDInter747",
"DDInter160"
] | Fludrocortisone | Bacillus calmette-guerin substrain tice live antigen | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
870,
25,
962
]
],
[
[
870,
64,
1057
],
[
1057,
25,
962
]
],
[
[
870,
24,
1213
],
[
1213,
25,
962
]
],
[
[
870,
24,
270
],
[
270,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etane... | Fludrocortisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with... |
DB08899 | DB09048 | 129 | 555 | [
"DDInter649",
"DDInter1284"
] | Enzalutamide | Netupitant | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Major | 2 | [
[
[
129,
25,
555
]
],
[
[
129,
63,
1101
],
[
1101,
23,
555
]
],
[
[
129,
25,
466
],
[
466,
62,
555
]
],
[
[
129,
63,
254
],
[
254,
2... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Netupitant"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexaro... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Netupitant
Enzalutamide may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may ... |
DB06643 | DB06772 | 1,136 | 310 | [
"DDInter500",
"DDInter259"
] | Denosumab | Cabazitaxel | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
1136,
24,
310
]
],
[
[
1136,
63,
973
],
[
973,
24,
310
]
],
[
[
1136,
24,
351
],
[
351,
63,
310
]
],
[
[
1136,
24,
375
],
[
375,
... | [
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribocic... |
DB00322 | DB00361 | 141 | 134 | [
"DDInter742",
"DDInter1939"
] | Floxuridine | Vinorelbine | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC . It is a third-generation vinca alkaloid. The introduction of third... | Moderate | 1 | [
[
[
141,
24,
134
]
],
[
[
141,
24,
147
],
[
147,
63,
134
]
],
[
[
141,
7,
1843
],
[
1843,
46,
134
]
],
[
[
141,
18,
3166
],
[
3166,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine
Floxuridine (Compound) upregulates PPARD (Gene) and PPARD (Gene) is upregulated by Vinorelbine (Compound)
Fl... |
DB00321 | DB09488 | 21 | 103 | [
"DDInter78",
"DDInter23"
] | Amitriptyline | Acrivastine | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
21,
24,
103
]
],
[
[
21,
1,
1405
],
[
1405,
24,
103
]
],
[
[
21,
24,
85
],
[
85,
24,
103
]
],
[
[
21,
35,
1264
],
[
1264,
24,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} ma... | Amitriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interacti... |
DB04865 | DB06335 | 4 | 761 | [
"DDInter1335",
"DDInter1646"
] | Omacetaxine mepesuccinate | Saxagliptin | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
4,
24,
761
]
],
[
[
4,
24,
1491
],
[
1491,
63,
761
]
],
[
[
4,
63,
1573
],
[
1573,
24,
761
]
],
[
[
4,
25,
283
],
[
283,
63,
... | [
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when... |
DB00214 | DB00916 | 1,028 | 112 | [
"DDInter1836",
"DDInter1202"
] | Torasemide | Metronidazole | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
1028,
24,
112
]
],
[
[
1028,
6,
3486
],
[
3486,
45,
112
]
],
[
[
1028,
21,
29310
],
[
29310,
60,
112
]
],
[
[
1028,
24,
11
],
[
11,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound... | Torasemide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Torasemide (Compound) causes Toxic epidermal necrolysis (Side Effect) and Toxic epidermal necrolysis (Side Effect) is caused by Metronidazole (Compound)
Torasemide may cause a moderate interaction that could exacerbate dise... |
DB00655 | DB00912 | 559 | 473 | [
"DDInter682",
"DDInter1581"
] | Estrone | Repaglinide | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
559,
24,
473
]
],
[
[
559,
6,
1829
],
[
1829,
45,
473
]
],
[
[
559,
21,
28873
],
[
28873,
60,
473
]
],
[
[
559,
24,
609
],
[
609,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Rep... | Estrone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Estrone (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Repaglinide (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarith... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.